Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers.

摘要: A large number of potential tis- sue biomarkers has been proposed for brain tumors. However, hardly any have ad- opted routine clinical use, so far. For most candidate substantial controversy exists with regard to their usefulness in clini- cal practice. The multidisciplinary neuroon- cology taskforce the Vienna Comprehen- sive Cancer Center Central Nervous System Unit (CCC-CNS) addressed this issue and elaborated a four-tiered levels-of-evidence system assessing analytical performance (reliability test result) perfor- mance (prognostic or predictive) based on consensually defined criteria. also agreed that only biomarker candidates should be considered as ready which meet quality stan- dards both, mance. Applying sys- tem MGMT, IDH1, 1p19q, Ki67, MYCC, MYCN β-catenin, immunohisto- chemical IDH1 mutation testing patients diffuse gliomas is supported by sufficient evidence order unequivocally quali- fied use. other lack published suf- ficiently high and, some cases, limits evidence-based confirmation utility. markers, no common standard laboratory exists. We conclude that, at present, there strong need studies specifically address tu- mor biomarkers. In addition, standardization needed. aim reg- ularly challenge update present clas- sification systematically clarify current translational status tumor identify specific re- search needs accelerating pace.